Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its U.S. subsidiary Eisai Inc. has launched its in-house discovered orexin receptor antagonist DAYVIGO??(lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in the U.S. on June 1, 2020.
AbbVie GK (Headquarters: Minato-ku, Tokyo; President: James Feliciano, hereafter “AbbVie”) and Eisai Co., Ltd. (Headquarters: Tokyo; CEO: Haruo Naito, hereafter “Eisai”) today announced an approval of partial changes in the marketing approval of HUMIRA??(generic name: adalimumab [recombinant], hereafter “HUMIRA”), a fully human anti- TNFα monoclonal antibody, for additional dosage and administration, specifically, to add an 80mg every-other-week (Q2W) regimen as a treatment option for patients with hidradenitis suppurativa (hereafter “HS”) after the first 4 weeks of treatment.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate (multikinase inhibitor, product name: LENVIMA?, “l(fā)envatinib”) and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN?, “eribulin”) will be given at the American Society of Clinical Oncology (ASCO20 Virtual Scientific Program*), from May 29 to 31, 2020.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) announced today that it has been selected as “Most Honored Company” and has been ranked first place overall in the Biotechnology & Pharmaceuticals sector of “The All-Japan Executive Team”, released by the US financial information magazine “Institutional Investor”. This selection is based on Eisai’s being ranked first place in “Best CEOs” and “Best CFOs”, respectively, in the sector.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Seikagaku Corporation (Headquarters: Tokyo, President: Ken Mizutani, “Seikagaku”) announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku.
The 6th Gastrointestinal & Liver Disease Treatment Forum (hereinafter referred to as “GIVE”), which was hosted by Eisai China Inc. and consisted of two sessions, completed successfully on Mar. 20 and Mar. 27 separately. In order to avoid people gathering during the epidemic outbreak, the Forum was held online innovatively.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).
Eisai China Inc. kicked off the Empowering Neurology’s Future (ENF) successfully on Mar. 22, 2020. To avoid people gathering during the epidemic period, the forum is held innovatively online to start a brand-new ENF Season, which will last from March 22ndto April 28th?in seven sessions, one session per week.
In the face of the epidemic of COVID-19, a large number of patients with normal medical needs can not go to hospital to seek medical treatment, and their diseases can not be treated well, which seriously decreases the quality of life of patients.?Eisai China Holdings Ltd.?is joining hands with all sectors of society to fight against the epidemic, and escorting people to tide over the crisis.?
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and FUJI YAKUHIN CO., LTD. (Headquarters: Saitama, CEO: Masayuki Takayanagi, “FUJI YAKUHIN”) announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in China.
